A sGC stimulator, BAY102-1189 (Vericiguat), that works by sensitizing and increasing the activation of sGC in low NO environments, has been shown to be effective against artery and pulmonary hypertension [21,22]. This evidence concerns the gene SGCB and pulmonary arterial hypertension.